Nasdaq Etf Profile

IBB
 Etf
  

USD 120.17  2.54  2.16%   

Market Performance
0 of 100
Odds Of Distress
Over 71
Nasdaq Biotechnology is trading at 120.17 as of the 5th of July 2022, a 2.16% increase since the beginning of the trading day. The etf's open price was 117.63. Nasdaq Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Nasdaq Biotechnology Ishares are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of June 2022 and ending today, the 5th of July 2022. Click here to learn more.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. More on Nasdaq Biotechnology Ishares

Moving together with Nasdaq Biotechnology

0.9XMQualtrics International Tech BoostPairCorr
0.87MSFTMicrosoft Corp Earnings Call  In Two WeeksPairCorr

Moving against Nasdaq Biotechnology

0.51XOMExxon Mobil Corp TrendingPairCorr

Nasdaq Biotechnology Etf Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Nasdaq Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nasdaq Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Nasdaq Biotechnology generated a negative expected return over the last 90 days
Nasdaq Biotechnology has high likelihood to experience some financial distress in the next 2 years
The fund retains 99.93% of its assets under management (AUM) in equities
ChairmanGeorge Parker
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Nasdaq Biotechnology's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
IssueriShares
DescriptioniShares Biotechnology ETF
Inception Date2001-02-05
BenchmarkICE Biotechnology Index
Entity TypeRegulated Investment Company
Asset Under Management7.77 Billion
Average Trading Valume2.29 Million
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Portfolio ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Transfer AgentState Street Bank and Trust Company
Fiscal Year End31-Dec
ExchangeNASDAQ
Number of Constituents377
Market MakerLatour Trading
Total Expense0.45
Management Fee0.45
Nav Price113.21
Two Hundred Day Average136.61
Ytd-30.26%
Average Daily Volume In Three Month2.72M
Trailing Annual Dividend Rate0.39
Fifty Two Week Low104.29
As Of Date11th of May 2022
Trailing Annual Dividend Yield0.33%
Average Daily Volume Last 10 Day2.57M
Fifty Two Week High177.37
One Month-18.33%
Nasdaq Biotechnology Ishares [IBB] is traded in USA and was established 2001-02-05. The fund is classified under Health category within iShares family. Nasdaq Biotechnology currently have 7.49 B in assets under management (AUM). , while the total return for the last 3 years was 0.67%.
Check Nasdaq Biotechnology Probability Of Bankruptcy

Geographic Allocation (%)

Top Nasdaq Biotechnology Ishares Constituents

Nasdaq Biotechnology Target Price Odds Analysis

What are Nasdaq Biotechnology's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Nasdaq Biotechnology jumping above the current price in 90 days from now is about 45.61%. The Nasdaq Biotechnology Ishares probability density function shows the probability of Nasdaq Biotechnology etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the etf has a beta coefficient of 1.1286. This usually indicates Nasdaq Biotechnology Ishares market returns are sensitive to returns on the market. As the market goes up or down, Nasdaq Biotechnology is expected to follow. Additionally, the company has an alpha of 0.0797, implying that it can generate a 0.0797 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 120.17HorizonTargetOdds Above 120.17
54.20%90 days
 120.17 
45.61%
Based on a normal probability distribution, the odds of Nasdaq Biotechnology to move above the current price in 90 days from now is about 45.61 (This Nasdaq Biotechnology Ishares probability density function shows the probability of Nasdaq Etf to fall within a particular range of prices over 90 days) .

Nasdaq Biotechnology Top Holders

Nasdaq Biotechnology Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Nasdaq Biotechnology market risk premium is the additional return an investor will receive from holding Nasdaq Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nasdaq Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Nasdaq Biotechnology's alpha and beta are two of the key measurements used to evaluate Nasdaq Biotechnology's performance over the market, the standard measures of volatility play an important role as well.

Nasdaq Biotechnology Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Nasdaq Biotechnology Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Nasdaq Biotechnology price patterns.
.

Nasdaq Biotechnology Against Markets

Picking the right benchmark for Nasdaq Biotechnology etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nasdaq Biotechnology etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nasdaq Biotechnology is critical whether you are bullish or bearish towards Nasdaq Biotechnology Ishares at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nasdaq Biotechnology without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Investing Nasdaq Biotechnology Ishares

You need to understand the risk of investing before taking a position in Nasdaq Biotechnology. The danger of trading Nasdaq Biotechnology Ishares is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Nasdaq Biotechnology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Nasdaq Biotechnology. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Nasdaq Biotechnology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. Note that the Nasdaq Biotechnology information on this page should be used as a complementary analysis to other Nasdaq Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Nasdaq Etf analysis

When running Nasdaq Biotechnology price analysis, check to measure Nasdaq Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nasdaq Biotechnology is operating at the current time. Most of Nasdaq Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nasdaq Biotechnology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nasdaq Biotechnology's price. Additionally, you may evaluate how the addition of Nasdaq Biotechnology to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
The market value of Nasdaq Biotechnology is measured differently than its book value, which is the value of Nasdaq that is recorded on the company's balance sheet. Investors also form their own opinion of Nasdaq Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Nasdaq Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nasdaq Biotechnology's market value can be influenced by many factors that don't directly affect Nasdaq Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nasdaq Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine Nasdaq Biotechnology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nasdaq Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.